ResMed Inc. ( RMD ) Nowojorska Giełda Papierów Wartościowych

Cena: 273.48 ( 0.04% )

Aktualizacja 07-24 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Instruments & Supplies

Notowania:


Opis firmy:

Resmed Inc. opracowuje, produkuje, dystrybuuje i sprzedaje urządzenia medyczne i aplikacje w chmurze na rynkach opieki zdrowotnej. Firma działa w dwóch segmentach, snu i opiece oddechowej oraz oprogramowaniu jako usługa. Oferuje różne produkty i rozwiązania dla szeregu zaburzeń oddechowych, w tym technologii, które mają być stosowane w produktach medycznych i konsumenckich, urządzeniach wentylacyjnych, produktach diagnostycznych, systemach maski do użytku w szpitalu i domu, nakrycia głowy i innych akcesoriach, urządzeniach dentystycznych i oprogramowania opartym na oprogramowaniu w chmurze w celu zarządzania wynikami pacjentów, a także zapewniają klientów i procesów biznesowych. Firma zapewnia również AirView, system oparty na chmurze, który umożliwia zdalne monitorowanie i zmianę ustawień urządzeń pacjentów; Myair, spersonalizowana aplikacja do zarządzania terapią dla pacjentów z bezdechem sennym, który zapewnia narzędzia wsparcia, edukacji i rozwiązywania problemów w celu zwiększenia zaangażowania pacjentów i lepszej przestrzegania; U-Sleep, rozwiązanie monitorowania zgodności, które umożliwia domowe urządzenia medyczne (HME) usprawnić programy snu; Moduł łączności i roztwory śmigła; i portal śmigła. Oferuje rozwiązanie oprogramowania poza szpitalnym, takie jak Brightree Business Management Software and Service Solutions dla dostawców usług HME, apteki, infuzji domowej, ortezy i protetyki; MatrixCare Care Management i powiązane rozwiązania pomocnicze dla życia seniorów, wykwalifikowanych pielęgniarstwa, społeczności planu życia, zdrowia domowego, opieki domowej i organizacji hospicyjnych, a także powiązanych organizacji odpowiedzialnych; oraz HealthCareFirst, który oferuje elektroniczny dokumentacja zdrowia, oprogramowanie, usługi rozliczeniowe i kodujące oraz analizy dla agencji zdrowia domowego i hospicjum. Firma sprzedaje swoje produkty przede wszystkim na klinikach spania, domowych dealerów opieki zdrowotnej i szpitali za pośrednictwem sieci dystrybutorów i bezpośrednich sił sprzedaży w około 140 krajach. Resmed Inc. został założony w 1989 roku i ma siedzibę w San Diego w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 9 980
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 99.188
Ilość akcji: Brak danych
Debiut giełdowy: 1995-06-02
WWW: https://www.resmed.com
CEO: Mr. Michael J. Farrell BE, MBA, SM
Adres: 9001 Spectrum Center Boulevard
Siedziba: 92123 San Diego
ISIN: US7611521078
Wskaźniki finansowe
Kapitalizacja (USD) 40 099 551 960
Aktywa: 7 222 417 000
Cena: 273.48
Wskaźnik Altman Z-Score: 13.1
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 2
P/E: 30.7
Ilość akcji w obrocie: 99%
Średni wolumen: 909 209
Ilość akcji 146 627 000
Wskaźniki finansowe
Przychody TTM 4 807 485 000
Zobowiązania: 2 027 391 000
Przedział 52 tyg.: 196.43 - 274.0
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 8.9
P/E branży: 29.9
Beta: 0.687
Raport okresowy: 2025-07-31
WWW: https://www.resmed.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Brett A. Sandercock Chief Financial Officer 909 641 1967
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD Founder, Chair Emeritus & Director 430 209 1942
Mr. Michael J. Farrell BE, MBA, SM Chief Executive Officer & Chairman 2 868 666 1972
Mr. Robert A. Douglas Special Advisor 1 914 035 1960
Mr. Kaushik Ghoshal Chief Commercial Officer - SaaS 1 109 460 1969
Ms. Vered Keisar Chief People Officer 0 0
Ms. Amy Wakeham Chief Investor Relations Officer 0 0
Ms. Yvonne-Katrin Pucknat Chief Marketing Officer 0 0
Mr. Michael J. Rider Chief Legal Officer 0 1958
Mr. Jim Ellis Chief Compliance Officer 0 0
Lista ETF z ekspozycją na akcje ResMed Inc.
Symbol ETF Ilość akcji Wartość
VOO 4 177 015 1 022 491 501
VO 3 223 907 789 180 194
SPY 1 772 936 456 614 453
IVV 1 748 559 448 347 919
VUG 1 746 375 427 495 136
VOT 1 140 547 279 194 500
XLV 1 018 500 267 040 560
VIG 785 966 192 396 617
IHI 766 762 196 605 492
RSP 569 844 146 427 114
IWR 510 765 130 965 317
VHT 459 263 112 422 989
QUAL 344 715 88 577 966
SXR8.DE 341 635 87 598 691
CSP1.L 341 635 87 598 691
CSPX.AS 341 635 87 598 691
CSSPX.MI 341 635 87 598 691
GSPX.L 341 635 87 598 691
CSPX.L 341 635 87 598 691
IVW 317 166 81 324 499
IWD 249 501 63 974 560
SPHQ 246 887 63 440 083
SCHG 224 518 57 670 560
IWP 222 625 57 083 150
IWDD.AS 216 299 55 461 218
IWDG.L 216 299 55 461 218
IWDA.L 216 299 55 461 218
IWLE.DE 216 299 55 461 218
SWDA.L 216 299 55 461 218
IWDA.AS 216 299 55 461 218
EUNL.DE 216 299 55 461 218
SWDA.MI 216 299 55 461 218
SPLG 206 158 52 307 624
VUSA.L 198 969 35 835 161
VUSA.DE 198 969 41 482 577
VUSD.L 198 969 48 705 621
VUSA.AS 198 969 41 482 577
VUAA.MI 198 969 41 482 577
VUSA.MI 198 969 41 482 577
VUAA.L 198 969 48 705 621
SPYG 197 601 50 432 042
VV 170 560 41 751 382
IWS 163 142 41 831 289
SCHX 146 363 37 609 436
IWF 130 625 33 493 451
SPGP 127 881 32 860 301
DFAC 124 795 32 067 323
IUSG 116 231 29 802 734
IWB 104 211 26 720 756
VOOG 92 541 22 653 111
DGRO 92 068 23 607 155
JQUA 79 615 20 540 670
IXJ 78 658 20 168 790
IYH 78 641 20 164 422
COWG 77 260 19 852 729
DGRW 77 251 19 261 764
IMCG 70 503 18 077 649
IUHC.L 68 930 17 674 222
QDVG.DE 68 930 17 674 222
IUHE.AS 68 930 17 674 222
IHCU.L 68 930 17 674 222
VWRP.L 68 761 12 384 147
VWRD.L 68 761 16 832 005
VWRL.L 68 761 12 384 147
VGWL.DE 68 761 14 335 818
VWCE.DE 68 761 14 335 818
FHLC 62 935 16 103 807
JHMM 59 103 14 637 448
VONV 56 866 13 920 228
IUSA.DE 53 184 13 636 867
IUSA.AS 53 184 13 636 867
IDUS.L 53 184 13 636 867
IUSA.L 53 184 13 636 867
VONG 49 050 12 006 949
RSPH 47 816 12 286 799
FXH 46 656 11 963 064
RPG 45 234 11 623 328
SASU.L 42 242 10 831 377
SAUA.MI 42 242 10 831 377
SLUS.DE 42 242 10 831 377
SGAS.DE 42 242 10 831 377
SDUS.L 42 242 10 831 377
GPSA.L 42 242 10 831 377
LSPX.L 41 462 10 613 442
SP5L.L 41 462 10 613 442
SP5H.PA 41 462 10 613 442
6TVM.DE 41 462 10 613 442
LSPU.L 41 462 10 613 442
ETFSP500.WA 41 462 10 613 442
LYP2.DE 41 462 10 613 442
I500.L 40 764 10 513 443
I50D.AS 40 764 10 513 443
I500.AS 40 764 10 513 443
QDF 39 468 10 103 018
DFUS 39 378 10 118 570
IWV 39 007 10 001 911
ACWI 38 855 9 962 853
ISAC.L 38 811 9 951 546
IUSQ.DE 38 811 9 951 546
SSAC.L 38 811 9 951 546
EWSP.L 36 081 9 251 529
ISPE.L 36 081 9 251 529
OMFL 35 912 9 227 947
ESGV 31 634 7 081 270
SPTM 27 291 6 997 526
FNDX 26 498 6 808 926
XSP.TO 24 827 8 685 130
DFAU 23 202 5 961 985
QGRW 22 612 5 638 076
VONE 22 396 5 482 316
PBUS 21 864 5 618 173
SMOT 21 495 5 500 140
IVV.AX 20 286 7 984 404
UMDV.AS 20 273 5 198 300
IUSE.L 19 857 5 091 641
IBCF.DE 19 857 5 091 641
5ESG.L 19 184 4 929 569
XUS.TO 18 804 6 578 108
5ESGE.MI 18 217 4 681 072
S5SG.DE 18 217 4 681 072
GINN 17 739 452 295
IXJ.AX 17 724 6 976 320
GSLC 17 619 4 527 378
AVUS 17 530 4 504 508
IUQD.L 17 347 4 447 977
QDVB.DE 17 347 4 447 977
IUQF.L 17 347 4 447 977
IUQA.L 17 347 4 447 977
KOMP 17 006 4 351 174
IWFQ.L 16 161 4 143 736
IWQU.L 16 161 4 143 736
IS3Q.DE 16 161 4 143 736
BUL 15 080 3 874 956
EDMU.SW 15 076 3 865 706
EEDG.L 15 076 3 865 706
EEDS.L 15 076 3 865 706
CBUC.DE 15 076 3 865 706
OM3L.DE 15 076 3 865 706
EDMU.DE 15 076 3 865 706
VGVE.DE 15 063 3 140 449
VGVF.DE 15 063 3 140 449
VDEV.L 15 063 3 687 271
VEVE.L 15 063 2 712 910
VHVE.L 15 063 3 687 271
S5SD.DE 14 115 3 626 980
IMCB 14 068 3 607 204
KRMA 14 027 3 590 631
SSO 13 954 3 585 619
ILCG 13 949 3 576 626
BIBL 13 730 3 528 060
BBUS 13 656 3 523 248
XHE 12 100 3 211 917
UB0A.L 12 078 3 103 657
AWESGS.SW 12 009 3 085 782
JREG.L 11 735 3 011 083
JGRE.L 11 735 3 011 083
JRDG.L 11 735 3 011 083
JREG.DE 11 735 3 011 083
FMDE 11 472 2 935 455
QLC 11 400 2 918 172
VTHR 11 365 2 782 038
SNAW.DE 11 342 2 908 273
SDWD.L 11 342 2 908 273
SAWD.L 11 342 2 908 273
S6DW.DE 11 342 2 908 273
VNRT.DE 11 012 2 295 865
VNRT.L 11 012 1 983 307
VNRG.L 11 012 1 983 307
VNRA.DE 11 012 2 295 865
VNRA.L 11 012 2 695 627
VDNR.L 11 012 2 695 627
SCHK 10 990 2 835 420
SPXL 10 916 2 793 186
PRF 10 896 2 799 836
EUSA 10 832 2 777 480
PTH 10 701 2 749 728
GSEW 10 073 2 588 358
FTC 10 066 2 581 023
PINK 10 005 2 560 079
URTH 9 862 2 528 743
QDEF 9 520 2 436 929
ANX.PA 9 241 2 365 511
ANXG.L 9 241 2 365 511
HNDX.DE 9 241 2 365 511
ANXU.L 9 241 2 365 511
6AQQ.DE 9 241 2 365 511
PTLC 9 241 2 374 567
SPYI 9 079 2 332 939
UBU7.DE 8 888 2 283 825
UETW.DE 8 888 2 283 825
UBU3.DE 8 887 2 283 547
UC04.L 8 887 2 283 547
UC03.L 8 887 2 283 547
XYLD 8 883 2 273 870
DLN 8 846 2 205 661
USXF 8 516 2 183 646
SNPE 8 137 2 090 883
GSUS 7 237 1 859 619
GSID 7 237 1 859 619
XHC.TO 7 185 2 513 449
CATH 6 876 1 760 118
XUU.TO 6 753 2 367 660
UPRO 6 716 1 725 743
XEQT.TO 6 468 2 262 767
DFSU 6 455 1 658 676
RWL 6 347 1 630 925
SPYX 6 292 1 607 770
IYY 6 269 1 607 541
ONEV 6 125 1 578 136
EDOC 6 043 1 329 097
ISDW.L 5 894 1 511 181
ISWD.L 5 894 1 511 181
ISWD.SW 5 894 1 511 181
SPUS 5 892 1 514 008
JOET 5 876 1 490 623
QUS 5 864 1 502 768
JPUS 5 797 1 495 626
CSM 5 730 1 472 380
VFMO 5 657 1 266 319
JPME 5 548 1 431 384
CSUS.L 5 510 1 412 766
CSUS.SW 5 510 1 412 766
SXR4.DE 5 510 1 412 766
CU1.L 5 510 1 412 766
TTAC 5 430 1 238 281
JHML 5 363 1 328 200
DCOR 5 351 1 374 992
ROUS 5 299 1 355 908
USPG.L 5 199 1 336 047
GUSA 4 899 1 258 847
IHVV.AX 4 866 1 915 336
CLSE 4 765 1 224 414
EFIV 4 572 1 181 768
USMF 4 530 1 159 272
UEQD.DE 4 488 1 153 361
QVML 4 299 1 104 671
PFM 4 231 1 087 197
IUSZ.L 4 194 1 075 377
QDVC.DE 4 194 1 075 377
IUSF.L 4 194 1 075 377
AVMC 3 850 989 296
UBU9.DE 3 826 983 010
UC13.L 3 826 983 010
HLAL 3 786 807 743
TMFC 3 773 0
PTL 3 615 928 910
XAW.TO 3 589 1 255 454
CFA 3 555 913 492
FDLS 3 441 884 199
WTDM.DE 3 379 864 719
DGRE.MI 3 379 864 719
DGRG.L 3 379 864 719
DGRW.L 3 379 864 719
DGRA.L 3 379 864 719
DGRB.L 3 379 864 719
DGRP.L 3 379 864 719
DTEC 3 369 865 698
IDNA.L 3 347 858 246
IQQN.DE 3 347 858 246
INAA.L 3 347 858 246
INAA.SW 3 347 858 246
FMED 3 226 825 468
IWLD.AX 3 166 1 246 134
ISUS.L 3 155 808 910
ISDU.L 3 155 808 910
EGMW.L 3 152 808 139
EMND.DE 3 152 808 139
EDMW.DE 3 152 808 139
EEWG.L 3 152 808 139
EEWD.L 3 152 808 139
UBU5.DE 3 093 794 835
UC07.L 3 093 794 835
CURE 3 074 786 575
FTQI 3 028 776 409
TILT 2 945 753 861
GPIX 2 871 737 732
WHCS.AS 2 849 730 537
CBUF.DE 2 849 730 537
WHCA.AS 2 849 730 537
UC68.L 2 834 728 215
WRDEUA.MI 2 834 728 215
ILCB 2 828 725 141
UIM7.DE 2 827 726 506
GGRG.L 2 810 719 107
GGRA.L 2 810 719 107
WTEM.DE 2 810 719 107
GGRE.MI 2 810 719 107
GGRW.L 2 810 719 107
GGRP.L 2 810 719 107
GGRB.L 2 810 719 107
CFO 2 810 722 057
UBUX.DE 2 746 705 637
MODL 2 736 703 042
NTSX 2 649 660 501
IGUS.L 2 647 678 634
CBUM.DE 2 625 672 978
ESPX.AS 2 625 672 978
QDPL 2 561 658 074
IWDC.SW 2 555 655 164
VFMF 2 546 569 922
UPAD.L 2 521 646 511
UPAB.AS 2 521 646 511
SIZE 2 479 635 719
STRV 2 473 635 462
CDX 2 465 630 658
DRUP 2 446 0
DTD 2 387 595 174
ISPY 2 372 609 509
JPGL.L 2 358 605 039
JPLG.L 2 358 605 039
JPGL.DE 2 358 605 039
UBUT.DE 2 341 601 415
UC99.L 2 341 601 415
PSET 2 261 578 544
DFVX 2 257 579 958
EQAL 2 250 578 160
HAPI 2 172 555 771
V3AL.L 2 153 527 032
V3AA.L 2 153 527 032
RSPA 2 139 549 637
IQSU 1 990 511 350
EPS 1 977 492 945
IHWL.AX 1 938 762 794
QIS 1 907 488 061
IUSC.SW 1 906 488 773
USNZ 1 866 479 487
USPA.L 1 863 472 605
WPAD.AS 1 851 474 605
WPAB.AS 1 851 474 605
WPAB.SW 1 851 474 605
XWD.TO 1 802 632 913
AVLC 1 725 443 256
XUSR.TO 1 676 586 320
IWFS.L 1 578 404 712
IS3T.DE 1 578 404 712
IWSZ.L 1 578 404 712
RXL 1 571 403 684
AFLG 1 555 398 717
DEUS 1 525 391 864
UC67.L 1 506 387 086
UIM6.DE 1 503 386 177
FDHT 1 475 377 423
JMID 1 448 372 078
GVUS 1 432 367 966
UBUJ.DE 1 396 358 779
MFUS 1 367 352 686
JUST 1 344 345 354
KOKU 1 338 343 812
XVV 1 264 324 797
FNDB 1 230 317 340
ESGA 1 228 230 201
FAD 1 187 304 358
EKG 1 187 304 358
IUS 1 115 286 510
BLES 1 109 284 968
HCMT 1 069 273 535
USCHWH.SW 1 036 266 203
DFND 986 253 362
XUH.TO 965 247 341
OALC 919 236 146
CRTC 898 230 750
XQLT.TO 890 311 240
DXUV 884 227 152
SPXT 862 221 499
BOUT 798 205 054
ONEO 743 190 214
R1VL.L 726 186 153
VLU 721 185 515
IGWD.L 645 165 373
SZNE 575 147 752
WINC.L 560 143 640
AVSU 536 137 730
R1GR.L 514 131 794
LSEQ 499 127 684
NZAC 492 126 216
SPUU 458 117 193
IE00BHXMHL11.SG 454 116 646
STXD 450 115 632
TOK 442 113 319
MAGA 424 108 735
DUBS 418 107 409
PBP 415 106 638
GGUS 415 106 638
STXG 413 106 124
VMO.TO 412 132 736
ANEW 370 95 075
GEQT.TO 364 127 394
QWLD 359 92 146
ONOF 344 88 057
FRUE.L 325 82 446
FLXU.DE 325 82 446
FLXU.L 325 82 446
GGRO.TO 322 112 543
HQGO 302 77 275
USUE.DE 264 67 900
USFM.L 264 67 900
CRBN 261 66 809
NACP 253 65 010
MMTM 249 63 753
QARP 240 61 670
GBAL.TO 212 74 205
SPXN 208 53 447
SPXE 192 49 336
MDEV 177 45 384
PHDG 168 43 169
XYLG 155 39 676
SNPG 152 39 057
XMAG 137 35 203
XRMI 133 34 045
BBDD.L 122 31 303
BBUS.L 122 31 303
BBSU.L 122 31 303
BBUS.DE 122 31 303
EVUS 79 20 299
NTSX.MI 54 13 819
NTSX.L 54 13 819
UQLT.L 49 12 593
GCNS.TO 45 15 689
INRO 41 10 461
XTR.TO 40 10 259
JCTR 32 8 256
XCLR 10 2 559
AMEW.DE 8 2 047
CW8.PA 8 2 047
CW8U.L 8 2 047
CW8G.L 8 2 047
XTR 5 1 279
IE00BN4Q0370.SG 0 0
PXS.TO 0 0
EQL.TO 0 0
ESG.TO 0 0
FFLS -2 100 -539 616
Wiadomości dla ResMed Inc.
Tytuł Treść Źródło Aktualizacja Link
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans' dreams to life over a six-week period. globenewswire.com 2025-05-15 13:00:00 Czytaj oryginał (ang.)
Top 15 High-Growth Dividend Stocks To Consider For May 2025 My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued. seekingalpha.com 2025-05-02 15:21:26 Czytaj oryginał (ang.)
Why ResMed (RMD) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-05-01 14:46:10 Czytaj oryginał (ang.)
Resmed Acquires VirtuOx Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers globenewswire.com 2025-05-01 13:00:00 Czytaj oryginał (ang.)
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-04-25 14:55:47 Czytaj oryginał (ang.)
Buy These 5 Low-Leverage Stocks to Counter Market Volatility The crux of safe investment lies in choosing a company that is not burdened with debt. You can buy BILI, KINS, ENGIY, ASML and RMD. zacks.com 2025-04-25 12:10:39 Czytaj oryginał (ang.)
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36. benzinga.com 2025-04-24 19:24:01 Czytaj oryginał (ang.)
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business. zacks.com 2025-04-24 12:25:37 Czytaj oryginał (ang.)
ResMed: Cornering The Market In Sleep Solutions ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions. seekingalpha.com 2025-04-24 09:12:03 Czytaj oryginał (ang.)
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Margaret Kaczor - William Blair Davin Thillainathan - Goldman Sachs Anthony Petrone - Mizuho Group David Low - JPMorgan Saul Hadassin - Barrenjoey Dan Hurren - MST Matt Taylor - Jefferies Steve Wheen - Jarden David Bailey - Morgan Stanley Brett Fishbin - KeyBanc Capital Markets Operator Greetings, and welcome to the Q3 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. seekingalpha.com 2025-04-23 23:16:19 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-04-23 23:00:42 Czytaj oryginał (ang.)
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago. zacks.com 2025-04-23 22:20:40 Czytaj oryginał (ang.)
ResMed slightly beats quarterly profit estimates on sleep devices demand Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. reuters.com 2025-04-23 21:08:44 Czytaj oryginał (ang.)
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com globenewswire.com 2025-04-23 20:05:00 Czytaj oryginał (ang.)
Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community globenewswire.com 2025-04-21 21:00:00 Czytaj oryginał (ang.)
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. zacks.com 2025-04-17 14:20:51 Czytaj oryginał (ang.)
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-16 15:06:27 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-15 14:45:36 Czytaj oryginał (ang.)
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2025-04-08 13:41:12 Czytaj oryginał (ang.)
RMD Stock Benefits From the Launch of NightOwl Across US Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home. zacks.com 2025-04-04 13:10:39 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-02-26 12:45:24 Czytaj oryginał (ang.)
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships globenewswire.com 2025-02-26 05:00:00 Czytaj oryginał (ang.)
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD) ResMed (RMD) could produce exceptional returns because of its solid growth attributes. zacks.com 2025-02-20 15:45:19 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com 2025-02-14 12:56:10 Czytaj oryginał (ang.)
Jan De Witte joins GHO Capital as Operating Partner Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. globenewswire.com 2025-02-11 06:30:00 Czytaj oryginał (ang.)
Why ResMed (RMD) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-02-10 12:47:19 Czytaj oryginał (ang.)
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. seekingalpha.com 2025-02-10 12:38:23 Czytaj oryginał (ang.)
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic. zacks.com 2025-02-05 15:15:31 Czytaj oryginał (ang.)
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market. zacks.com 2025-02-04 15:45:33 Czytaj oryginał (ang.)
Stock Of The Day: Trading The Range In ResMed ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%. benzinga.com 2025-02-03 14:59:07 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-02-03 12:55:54 Czytaj oryginał (ang.)
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run? ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2025-01-31 12:16:13 Czytaj oryginał (ang.)
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call. seekingalpha.com 2025-01-30 23:10:41 Czytaj oryginał (ang.)
ResMed: Digital Health Drives Q2 Growth ResMed (RMD 1.89%), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion. fool.com 2025-01-30 21:44:26 Czytaj oryginał (ang.)
Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-01-30 21:30:31 Czytaj oryginał (ang.)
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago. zacks.com 2025-01-30 20:21:09 Czytaj oryginał (ang.)
ResMed beats quarterly profit estimates on demand for sleep disorder devices ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. reuters.com 2025-01-30 19:21:55 Czytaj oryginał (ang.)
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com globenewswire.com 2025-01-30 18:05:00 Czytaj oryginał (ang.)
ResMed (RMD) Earnings Expected to Grow: Should You Buy? ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-01-23 13:06:45 Czytaj oryginał (ang.)
5 Sectors and Stocks Set to Shine This Earnings Season We have highlighted stocks from the sectors that are expected to move higher this earnings season. zacks.com 2025-01-14 14:56:11 Czytaj oryginał (ang.)
ResMed Gains 37.8% in a Year: What's Driving the Stock? RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning. zacks.com 2025-01-03 11:35:49 Czytaj oryginał (ang.)
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, RJF and KBR are some stocks that hold promise. zacks.com 2025-01-03 11:35:38 Czytaj oryginał (ang.)
My Top 15 High Growth Dividend Stocks For January 2025 The SPDR S&P 500 ETF Trust ended 2024 on a sour note, losing 2.41% in December and finishing the year up 24.89%. The Top 15 dividend growth stocks for January 2025 offer an average dividend yield of 1.21% and appear to be about 27% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.33% compound annual growth rate. seekingalpha.com 2025-01-03 00:49:14 Czytaj oryginał (ang.)
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2024-12-31 15:25:26 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-30 12:46:47 Czytaj oryginał (ang.)
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs. investopedia.com 2024-12-23 16:59:31 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love ResMed (RMD) ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2024-12-23 15:46:06 Czytaj oryginał (ang.)
2 Sleep Apnea Stocks in Focus Today Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. schaeffersresearch.com 2024-12-23 12:51:58 Czytaj oryginał (ang.)
Why ResMed (RMD) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-23 12:46:11 Czytaj oryginał (ang.)
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025 Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. zacks.com 2024-12-20 12:26:08 Czytaj oryginał (ang.)
Why ResMed (RMD) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-13 12:41:08 Czytaj oryginał (ang.)
RMD or PODD: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-12-12 14:41:20 Czytaj oryginał (ang.)
5 Solid Dividend Growth Stocks to Buy Now InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands seem excellent choices for your portfolio. zacks.com 2024-12-12 12:15:40 Czytaj oryginał (ang.)
Scoop Up These 3 GARP Stocks to Receive Handsome Returns The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RMD, OUT and CTAS are some stocks that hold promise. zacks.com 2024-12-09 11:10:36 Czytaj oryginał (ang.)
Here is Why Growth Investors Should Buy ResMed (RMD) Now ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2024-12-09 08:47:18 Czytaj oryginał (ang.)
4 Medical Product Stocks to Buy From a Prospective Industry An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors. zacks.com 2024-12-04 12:45:35 Czytaj oryginał (ang.)
Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41% globenewswire.com 2024-12-04 06:13:00 Czytaj oryginał (ang.)
Here's Why ResMed (RMD) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-03 12:55:53 Czytaj oryginał (ang.)
My Top 15 High-Growth Dividend Stocks For December 2024 The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and appear to be about 22% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 12.41% compound annual growth rate. seekingalpha.com 2024-12-02 08:00:00 Czytaj oryginał (ang.)
RMD vs. LMAT: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-11-26 14:40:45 Czytaj oryginał (ang.)